The goal of the CRC 1160
The Collaborative Research Center (CRC) 1160. “Immune-mediated pathology as a consequence of impaired immune reactions (IMPATH)” is a research consortium of clinical and basic immunologists exploring the basis of diseases mediated by the immune system.
The CRC sets out to challenge the traditional idea that an “overreaction” or “deviation“ of normal immune responses is pivotal to immune mediated pathology and that, consequently, immunosuppression is the appropriate therapeutic strategy for such disorders. Instead, the conceptual basis of the CRC is the idea that impaired immune reactions constitute a major prerequisite for immunopathology. This is what we call the “IMPATH paradox”. This paradox implies that immune reconstitution and/or immune stimulation rather than immunosuppression represent appropriate therapeutic principles for these forms of immunopathology.
News
Publications
Friedmann D, Payne KJ, Cousin V, Andrieux G, Meng K, Schlaak AE, Unger S, Klocperk A, Geier C, Gräwe K, Pfeiffer J, Jakob TF, Hausmann O, Anhut P, Shabani M, Kurowski K, Rogg M, Aumann K, Seidl M, Provaznik J, Benes V, Boerries M, Boettler T, Schell C, Goldacker S, Keller B, Bengsch B, Warnatz K. 2025. Expansion of a distinct cytotoxic CD4 TFH-cell cluster in lymph nodes of patients with complicated Common Variable Immunodeficiency. J Allergy Clin Immunol. 2025 Nov 26:S0091-6749(25)01144-3. doi: 10.1016/j.jaci.2025.09.032.
Liu J, Rogg M, Moos K, Sasanpour S, Strassl V, Jain M, Magassa S, Neubauer B, Braeg S, Saller BS, Weißer L, Bienaimé F, Gorka O, Boerries M, Viau A, Gross O, Schell C, Kuehn EW.2025. Inhibition of the inflammasome ameliorates orthologous polycystic kidney disease. Proc Natl Acad Sci U S A. 122(46):e2511204122. doi: 10.1073/pnas.2511204122.
Hund I, Hess ME, Andrieux G, Stomper J, Greve G, Niemöller C, Ma T, Uhl D, Grishina O, Thol F, Heuser M, Bug G, Crysandt M, Neubauer A, Duyster J, Döhner H, Boerries M, Lübbert M, Becker H. 2025. Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trial. Leukemia. 39(11):2816-2819. doi: 10.1038/s41375-025-02780-7.
Zwick M, Zinkel B, Spohr C, Rückert T, Halbach S, Shoumariyeh K, Scheid J, Baur AS, Braun LM, Angel M, Michaeli E, Todkar A, Nelde A, Märklin M, Holzmayer SJ, Dicks S, Boerries M, Duquesne S, Schlaak AE, Otto-Mora P, Bengsch B, Schiff M, Kissel S, Selle M, Follo M, Altmann H, Kunadt D, Illert AL, Walz JS, Walz G, Duyster J, Schetelig J, Brummer T, Zeiser R, Köhler N. 2025. FLT3-ITD Induces CMTM6 and Enhances Immune Escape in Acute Myeloid Leukemia. Cancer Res. Oct 3. doi: 10.1158/0008-5472.CAN-25-0349.
Gres V, Göcer M, Kolter J, Henneke P. 2025. Trained immunity in skin infections: Macrophages and beyond. Elife. 14:e106688. doi: 10.7554/eLife.106688.
Contact
Scientific Manager/Administration
Dr. Heike Ufheil
Institute for Immunodeficiency (IFI),
Center for Chronic Immunodeficiency (CCI)
Medical Center – University of Freiburg
